Exosome technologies

Exosome therapy is a relatively new concept, with  both challenges and significant opportunities

Why Exosomes?

Exosomes are nanosized vesicles (50-200nm) released naturally by cells. They are important effectors of cell communication. A key mechanism by which cell therapies work is via release and uptake of exosomes.

Some of the properties of exosomes are:

  • they contain unique mix of molecular cargo (including miRNA, proteins, peptides, lipids) that underpin
  • their biological effect
  • they have homing capabilities that allow them to travel to the site of injury or disease
  • their immunomodulatory properties helps normalise the immune system
  • being low/non-immunogenic
  • they are not rejected by the bodythey have other bioactive properties based on parent cell e.g. angiogenesis, anti-fibrotic, regenerative, etc.

A: Cell

B: Exosome

VivaZome = Nature + Technology

VivaZome is leveraging the best that nature and technology has to offer:

Native Exosomes
  • Cell Source is key; exploit unique cell attributes
  • Angiogenic, anti-fibrotic, immunomodulatory exosomes
  • Multiple cells types screened based on their native biological function
  • Exosome quantity and quality assessed
  • Cell Engineering for immortalisation and enhanced function
Universal Manufacturing Process
  • Customised, best-in-class technology
  • Proprietary components to complement established technology from leading suppliers 
  • Proprietary cells for manufacture
  • Underpinned by extensive characterisation, molecular cargo analysis, potency assays that link attributes to function and clinical targets 

Exosomes as a therapeutic opportunity

Exosome therapy is a relatively new concept, with  both challenges and significant opportunities.

VivaZome’s focus:
Novel, scalable processes and technology

Special challenges with large- scale separation and concentration technology and analytics


No registered exosome therapies

Limited but growing clinical experience with exosomes


Evolving exosome-specific guidance from regulatory agencies

Growing number of industry players

Sophisticated exosome analytic technology for product specification

Clinical Targets

LEAD Angiogenic Program

  • Critical limb ischemia
  • Cardiac ischemia
  • Cerebral ischemia

Treatment for Critical Limb Ischemia costs >US$10 billion per annum in USA alone

Anti-Fibrotic Program

  • Chronic kidney disease
  • Non-alcoholic steatohepatitis  

USA expenditure for CKD was >US$64billion in 2015

Neurological Repair Program

  • Stroke
  • Traumatic brain injury
  • Neurodegenerative diseases

In 2016, stroke was the second largest cause of death globally